Nanocomposite hydrogel acupoint therapy for sustained pregabalin delivery and long-term neuropathic pain relief.

Researchers have developed a new treatment approach that combines modern nanotechnology with traditional acupuncture principles to provide long-lasting relief for nerve pain. The study focused on creating a special gel containing the pain medication pregabalin (commonly known as Lyrica) that can be injected at a specific acupuncture point called Huantiao (GB30), located near the hip. This innovative gel is designed to release the medication slowly over an extended period, rather than all at once.

In laboratory studies using rat models of nerve pain caused by chemotherapy drugs and nerve injury, the researchers found impressive results. The gel-based treatment provided steady pain relief lasting up to 20 days from a single injection, while traditional medication wore off much more quickly. Blood tests showed that the medication from the gel peaked at 16 hours after injection and remained in the system for up to 12 days, compared to just 4 hours for standard medication. Importantly, the animals receiving this treatment showed significant improvements in sensitivity to touch and cold without experiencing sedation or drowsiness—common side effects of nerve pain medications.

What makes this approach particularly promising for patients is the combination of sustained drug delivery with the therapeutic effects of acupuncture point stimulation. By targeting a specific acupuncture point, the treatment may work through multiple mechanisms to reduce pain while minimizing side effects. This could mean fewer injections, more consistent pain control, and better quality of life for people suffering from chronic nerve pain conditions. If you're considering acupuncture or alternative pain management approaches, consult with a licensed acupuncturist or healthcare provider experienced in integrative pain management.

This preclinical study evaluated a nanocomposite hydrogel system (PG@PLGA-gels) combining pregabalin-loaded PLGA nanoparticles within a chitosan/β-glycerophosphate thermosensitive hydrogel for acupoint administration at GB30 (Huantiao). In rat models of paclitaxel-induced peripheral neuropathy and chronic constriction injury, the formulation demonstrated sustained release pharmacokinetics with peak plasma concentration at 16 hours (7985.94 ± 96.19 ng/mL) versus 4 hours for PG solution (4928.33 ± 124.71 ng/mL), maintaining detectable levels for 288 hours. Single acupoint injection provided significant reduction in mechanical and cold allodynia from day 8 through day 20 post-administration without observable sedation. The system achieved 2.6-fold increased systemic exposure with 46.44% initial 24-hour release and sustained delivery over 12 days. Spinal cord transcriptomic analysis revealed modulation of pathways involving neuronal structure, synaptic organization, and excitatory signaling. This acupoint nanomedicine platform demonstrates potential for prolonged analgesia in neuropathic pain management through combined pharmacological and acupoint-mediated mechanisms with reduced adverse effect profile.